Precision NanoSystems NanoAssemblr Spark for screening of nanomedicine formulations

Tuesday, 01 March, 2022 | Supplied by: ATA Scientific Pty Ltd

Precision NanoSystems NanoAssemblr Spark for screening of nanomedicine formulations

Nanomedicines are believed to represent the next era in drug innovation, with improved performance, reduced side effects and new treatment strategies for otherwise ‘undruggable’ targets like personalised medicine. Consisting of active pharmaceutical ingredients (API) such as small molecules or nucleic acids, nanomedicines are packaged into nano-sized carriers like lipids and polymers that are designed to protect the cargo, enhance solubility and control distribution and targeted release.

Screening active ingredients, excipients and formulation conditions are important in the discovery and early development stages. Traditional methods used to develop nanomedicines can present several challenges. Ingredients can be costly or in limited supply, while the final product can lack consistency, have low throughput, be a slow and laborious process and be difficult to scale. The NanoAssemblr series from Precision NanoSystems is enabling drug innovators to overcome these and many other challenges by making purpose-designed manufacturing technology to support all stages of nanomedicine development.

The NanoAssemblr Spark offers the ability to formulate small-scale uniform particles using microlitre volumes quickly and reproducibly, with near complete sample recovery. Requiring little or no training, users can simply add starting materials into wells, push a button and pipette completed formulations in less than 10 s, allowing hundreds of formulations to be made in hours. Electronic control minimises batch-to-batch and user variability. Plus, formulations can be made on demand in a sterile hood for immediate cell culture application, making the Spark suitable for screening formulations that use scarce or expensive APIs or excipients.

Precision NanoSystems’ GenVoy-ILM T Cell Kit for mRNA accelerates T cell therapy from an idea to clinical applications.

For more information: https://www.atascientific.com.au/products/nanoassemblr-spark/.

Online: www.atascientific.com.au
Phone: 02 9541 3500
Related Products

TOPTICA DFB pro 633 distributed-feedback laser

TOPTICA introduces the DFB pro 633, the latest in the company's range of mode-hop-free...

Anton Paar Litesizer DIF 500 particle sizer

Anton Paar has launched the Litesizer DIF 500 — a laser diffraction particle size...

HEMCO Model 24000 Vented Tabletop Workstation

HEMCO's Model 24000 Vented Tabletop Workstation is constructed of chemical-resistant,...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd